Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk
Pharmaceuticals · 11.07.2026 · 19 (7) · 1071
DOI: 10.3390/ph19071071 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 11.07.2026. Verfasst von Kyriakos E Kypreos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Laboratory, Department of Medicine, University of Patras, 26500 Rio Achaias, Greece. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Romania's National Recovery and Resiliance Plan, European Union, Andreas Mentzelopoulos Foundation.
Abstract (Originalsprache)
Despite major advances in lipid-lowering therapy and the widespread implementation of statins, ezetimibe, and PCSK9-targeted interventions, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide. Intensive lowering of low-density lipoprotein cholesterol (LDL-C) has substantially reduced cardiovascular events; however, a considerable degree of residual cardiovascular risk persists even among patients achieving very low LDL-C levels. This observation has shifted contemporary cardiovascular research toward a broader understanding of atherosclerosis as a multifactorial disorder involving triglyceride-rich lipoproteins (TRLs), apolipoprotein B (APOB)-containing particles, dysfunctional high-density lipoproteins (HDLs), lipoprotein(a) [Lp(a)], endothelial dysfunction, and chronic vascular inflammation. Emerging evidence further suggests that psychological and behavioral factors, including specific personality traits and chronic psychosocial stress, may contribute independently to cardiovascular disease susceptibility and outcomes. The present review summarizes emerging risk factors associated with residual cardiovascular risk and highlights novel therapeutic strategies beyond LDL-C lowering. Collectively, current evidence supports a transition from a simplistic LDL-C-centric paradigm toward a multiple risk factor approach for atherosclerosis prevention and treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacology Laboratory, Department of Medicine, University of Patras, 26500 Rio Achaias, Greece.
- Gene Regulation and Molecular Therapies Laboratory, Institute of Cellular Biology and Pathology, "Nicolae Simionescu" of the Romanian Academy, 050568 Bucharest, Romania.
- School of Sciences, Department of Life Sciences, European University Cyprus, Egkomi, Nicosia 2404, Cyprus.
ORCID-Profile: Kyriakos E Kypreos, Anca Violeta Gafencu, Ourania Andreopoulou, Maria Alemi, Marius Gabriel Multescu, Madalin Ghinea
Förderung
- Romania's National Recovery and Resiliance Plan
- European Union
- Andreas Mentzelopoulos Foundation
Zitieren
APA
Kypreos, K. E., Gafencu, A. V., Andreopoulou, O., Zvintzou, E., Marinos, K., Mparnia, V., Alemi, M., Daraban, B. S., Multescu, M. G., Ghinea, M., & Mirancea, O. (2026). Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk. Pharmaceuticals, 19(7), 1071. https://doi.org/10.3390/ph19071071
Vancouver
Kypreos KE, Gafencu AV, Andreopoulou O, Zvintzou E, Marinos K, Mparnia V, et al. Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk. Pharmaceuticals. 2026;19(7):1071. doi:10.3390/ph19071071
BibTeX
@article{Kypreos2026,
author = {Kypreos, Kyriakos E and Gafencu, Anca Violeta and Andreopoulou, Ourania and Zvintzou, Evangelia and Marinos, Konstantinos and Mparnia, Victoria and Alemi, Maria and Daraban, Bianca Sanziana and Multescu, Marius Gabriel and Ghinea, Madalin and Mirancea, Oana},
title = {Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1071},
doi = {10.3390/ph19071071}
}
EUVIMED